BIOFRONTERA Business Summary

Biofrontera Inc. (BFRI) is a U.S.-based biopharmaceutical company that generates revenue primarily through the commercialization of its flagship drug-device combination, Ameluz® (aminolevulinic acid hydrochloride) topical gel, and the RhodoLED® lamp series. The company’s business model is centered on the sale of these proprietary photodynamic therapy (PDT) products for the treatment of dermatological conditions, specifically actinic keratosis (AK) and superficial basal cell carcinoma (sBCC). In late 2024 and 2025, the company strategically transitioned from a high-cost transfer-pricing model with its former parent, Biofrontera AG, to a more profitable structure by acquiring full U.S. rights to its core assets, significantly improving its gross margins and path to cash flow breakeven. Biofrontera competes directly with major dermatology players such as Sun Pharmaceutical Industries, Galderma, Verrica Pharmaceuticals, and Evolus Inc. Within this landscape, Biofrontera positions itself as a specialized leader in red-light PDT technology, leveraging its unique nanoemulsion formulation to achieve deeper tissue penetration than competitors utilizing blue or green light therapies. The company is led by Founder, CEO, and Chairman Prof. Hermann Luebbert, PhD, a veteran biopharma executive who previously founded the German parent company Biofrontera AG and held senior research roles at Sandoz and Novartis. The executive team includes Chief Financial Officer Fred Leffler (Eugene Frederick Leffler III), a former McKinsey & Co. consultant with extensive experience in healthcare corporate finance, and Chief Commercial Officer George Jones, who joined in August 2025 with over 25 years of specialty pharmaceutical leadership from firms like Currax and Depomed. The Board of Directors features notable industry figures such as John J. Borer III of The Benchmark Company and Dr. Beth J. Hoffman, CEO of Origami Therapeutics. Significant institutional and insider backing includes Biofrontera AG and Beteiligungen Aktiengesellschaft Vv, providing a stable governance foundation as the company pursues FDA approvals for expanded clinical indications in 2026.